ДХИНГРА Капил (US),ХИГГИНС Брайан (US),КОЛИНСКИ Кеннет (US),ЛИ Ричард Дж. (US),ЛЕСТИНИ Брайан (US),ПЭКМЕН Кэтрин Е. (US),СУ Фей (US)
申请号：
RU2013110124/15
公开号：
RU2013110124A
申请日:
2011.08.16
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical product comprising (A) a first component that contains, as an active agent, {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-b] pyridin-3-carbonyl] -2,4 -difluorophenyl} propane-1-sulfonic acid amide or a pharmaceutically acceptable salt thereof； and (B) a second component that contains an EGFR inhibitor as an active agent； as a combined preparation for the simultaneous or sequential use in the treatment of a proliferative disorder, in particular cancer, more specifically colorectal cancer, melanoma and thyroid cancer, containing b-Raf with mutation V600.2. The pharmaceutical product according to claim 1 for the treatment of colorectal cancer, melanoma and thyroid cancer, containing b-Raf with a mutation V600E. The pharmaceutical product according to claim 1, wherein said EGFR inhibitor is erlotinib or a pharmaceutically acceptable salt thereof. The pharmaceutical product of claim 1, wherein said EGFR inhibitor is cetuximab. The pharmaceutical product according to claim 1, further comprising a third component (C), which comprises an topoisomerase inhibitor, in particular a type I topoisomerase inhibitor, as an active agent. The pharmaceutical product according to claim 5, wherein said topoisomerase inhibitor is irinotecan or a pharmaceutically acceptable salt thereof. The pharmaceutical product according to any one of claims 1 to 6, wherein {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-b] pyridin-3-carbonyl] -2,4-difluorophenyl} -amide propane -1-sulfonic acid or a pharmaceutically acceptable salt thereof is in an amorphous or substantially amorphous form. A kit consisting of: (A) a first component that contains {3- [5- (4-chloro-phenyl) 1H-pyrrolo [2,3-b] pyridine-3-carbonyl] -2,4 as an active agent -di1. Фармацевтический продукт, включающий (А) первый компонент, который содержит в качестве активного агента {3-[5-(4-хлорфенил)-1Н-пирроло[2,3-b]пиридин-3-карбонил]-2,4-дифторфенил}амид пропан-1-сульфокислоты или его фармацевтически приемлемую соль； и (В) вто
